Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34384555.
- Also identified by DOI 10.1016/j.jacc.2021.06.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although some progress has been made in the last 3 decades to increase the number of women in clinical cardiology trials, review of recent cardiovascular literature demonstrates that women and underrepresented minority women are still underrepresented in most clinical cardiology trials. This is especially notable in trials of patients with coronary artery disease, heart failure with reduced ejection fraction, and arrhythmia studies, especially those involving devices and procedures. Despite the call from National Institutes of Health, Food and Drug Administration, Institute of Medicine, and various professional societies, the gap remains. This paper seeks to identify the barriers for low enrollment and retention from patient, clinician, research team, study design, and system perspectives, and offers recommendations to improve recruitment and retention in the current era.
Medical subject headings
- Cardiology
- Cardiovascular Diseases
- Clinical Trials as Topic
- Patient Participation